Five North Louisiana researchers have been funded a total of $200,000 in the second cycle of the Office for Research Development and Administration’s (ORDA) Seed Funding Program.
Awardees are from the University of Louisiana at Monroe (ULM), LSU Health Sciences Center Shreveport (LSUHSCS) and Louisiana Tech University.
The Seed Funding Program, administrated by ORDA, a division of BRF, is part of ORDA’s mission to promote North Louisiana as a bioscience research hub, foster multidisciplinary research partnerships and leverage preclinical and clinical research to advance healthcare and economic development in the region.
The funding is intended to provide support for investigators to generate preliminary data and apply for extramural funding from government and/or private sources. Projects were peer reviewed by out-of-state reviewers and then by BRF’s internal committee.
This cycle’s focus area was Neuroscience/Neuroengineering, Neuroinformatics and Aging. ORDA’s first seed funding cycle, awarded in February of 2017, was focused in Neuroscience/Neuroengineering and Aging.
This cycle’s funded researchers and projects:
- ULM – $50,000 – Khalid El Sayed, Ph.D., Professor of Medicinal and Natural Products Chemistry, Department of Basic Pharmaceutical Sciences, School of Pharmacy
Project Title: Novel PCSK9-LDLR natural products-based inhibitor for the prevention of neurological disorders
Project’s Narrative: A novel class of anti-hyperlipidemia medications is developed with unique mechanism of action. The use of this natural product is expected to replace the current drugs, which induce wide array of side effects. This new drug is expected to protect the human brain and cardiovascular system against the harm caused by elevated blood cholesterol levels.
- ULM – $50,000 – Karen Briski, Ph.D., Professor, Pharmacology; Department Head, Department of Basic Pharmaceutical Sciences, School of Pharmacy
Project Title: Estrogen neuroprotection against hypoglycemic brain injury
Project’s Narrative: Severe hypoglycemia is a recurring complication of strict management of diabetes mellitus. Hypoglycemia causes nerve cell death in discrete brain areas, including the hippocampus, a structure that is critical for memory and learning. Anticipated new insight on neuroprotection afforded by locally generated neuro-estrogen against hypoglycemic injury can be leveraged to develop therapies aimed at preventing/minimizing brain damage in those patients.
- LSUHSCS – $50,000 – J. Steven Alexander, Ph.D., Professor, Molecular & Cellular Physiology
Project Title: Pilot alpha-syn glymphatic Tau stasis in experimental Parkinson’s Disease
Project’s Narrative: Tau and alpha-synuclein are toxic proteins which aggregate and cause injury to the substantia nigra in the brain often leading to more rapid progression of motor and cognitive disturbances in Parkinson’s disease (PD). Our research strongly suggests that deposition of Tau with alpha-synuclein intensifies Tau-mediated PD severity by limiting the clearance of these proteins in exosome / microparticulates from the brain via the glymphatic/paravascular pathways. The successful completion of these studies will determine how Tau and alpha-synuclein hasten and intensify the onset of PD, and provide a powerful mechanistic platform for diagnosing and staging PD and develop novel mechanism-based models for testing and developing PD therapeutics.
- Louisiana Tech University- $25,000 – Scott Poh, Ph.D., Assistant Professor, Chemistry and Biochemistry
Project Title: The use of novel electrochemical sensors to detect oxidative stress generated by macrophage in the brain
Project’s Narrative: During oxidative stress, the release of reactive oxygen species (ROS) or reactive nitrogen species (RNS) by macrophages (brain region mimic) will be investigated by a multiplexed novel microarray sensor. The sensor directly measures total antioxidant activity (TAA) by determining the overall electrochemical reducing power, and thus avoids the disadvantages of the classical fluorescence probing techniques.
- Louisiana Tech University – $25,000 – Yuri Lvov, Ph.D., Professor, Institute for Micromanufacturing
Project Title: Nanoclay based anti-aging drug formulations
Project’s Narrative: We will elaborate a novel assay for evaluation of aging effect of nanoclays using C. elegance nematodes as an animal in vivo model. Based on this assay, natural antiaging drugs formulations will be developed (permethrin and lawsone loaded into the clay nanotubes give 10-40 hrs sustained release). In commercialization, we focus on: 1) cosmetic antiaging skin formulations with tubule clay additives for sustained release of natural drugs and gray hair treatment; and 2) animal anti-parasite hair care products which are easier for approval.
ORDA, a division of BRF, was created in 2015 to seek and promote new research initiatives and provide support for the implementation of translational and clinical research at University Health, LSU Health Sciences Center Shreveport and other research entities of the region.